| European Case Law Identifier: | ECLI:EP:BA:2013:T050109.20130625 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 25 June 2013 | ||||||||
| Case number: | T 0501/09 | ||||||||
| Application number: | 96943576.7 | ||||||||
| IPC class: | C07K 16/32 C07K 16/46 C12N 5/20 C12N 5/10 A61K 39/395 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Apoptosis induced by monoclonal antibody anti-Her2 | ||||||||
| Applicant name: | Amgen Inc., | ||||||||
| Opponent name: | Fresenius Biotech GmbH | ||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of appeal/patentee - statement of grounds (not filed) Admissibility of appeal/opponent - appeal sufficiently substantiated (no) |
||||||||
| Catchwords: |
Admissibility of appeal, see points 2 to 8 |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t090501eu1.html
Date retrieved: 17 May 2021